Literature DB >> 21523720

Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.

Mieke Van Hemelrijck1, Hans Garmo, Lars Holmberg, Göran Walldius, Ingmar Jungner, Niklas Hammar, Mats Lambe.   

Abstract

BACKGROUND: In a cohort including 5112 prostate cancer (pCa) patients, the authors investigated associations among triglycerides (TG), total cholesterol (TC), and pCa while taking into account glucose.
METHODS: A cohort (n = 200,660) based on 4 groups of men, according to age at cohort entry, with TG, TC, and glucose measurements was selected from the Apolipoprotein MOrtality RISk (AMORIS) database. Of these, 5112 men developed pCa. Multivariate Cox proportional hazard models were used to analyze associations among TG, TC, and pCa. Competing risks were assessed graphically.
RESULTS: Age-stratified analyses for quartiles of TG, TC, and glucose showed a negative association between glucose and pCa risk (HR, 0.93; 95% CI, 0.86-1.01), 0.93 (0.86-1.01), 0.87 (0.81-0.94) for the second, third, and fourth quartiles compared with the first (P(trend) = .001). Stratified analysis by glucose levels (<6.11 or ≥ 6.11 mmol/L) showed a positive association between hypertriglyceridemia (TG ≥ 1.71 mmol/L) and pCa risk, when there were high glucose levels (HR, 1.23; 95% CI, 1.01-1.48). No association was found for hypercholesterolemia (TC ≥ 6.50 mmol/L). Competing risk analysis showed that protective effects of glucose were overestimated in conventional Cox proportional hazard models and strengthened positive findings between TG and pCa risk.
CONCLUSIONS: The authors'; findings supported the hypothesis that factors of the glucose and lipid metabolism influence pCa risk. Competing risk assessment showed that it is important to take into account the long natural history and age distribution of pCa when interpreting results. The authors'; findings indicate another reason to fight the increasing prevalence of obesity and dyslipidemia. 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21523720     DOI: 10.1002/cncr.25758

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  44 in total

Review 1.  [Obesity and prostate cancer. Role of adipocytokines and clinical implications].

Authors:  M R Hoda; N Mohammed; G Theil; K Fischer; P Fornara
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.

Authors:  Divya Seth; Hans Garmo; Annette Wigertz; Lars Holmberg; Niklas Hammar; Ingmar Jungner; Mats Lambe; Göran Walldius; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

3.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

4.  Does metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy?

Authors:  Onur Telli; Hasmet Sarici; Musa Ekici; Berat Cem Ozgur; Omer Gokhan Doluoglu; Muzaffer Eroglu; Tugba Akin Telli
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

Review 5.  Phenotypes and genotypes of high density lipoprotein cholesterol in exceptional longevity.

Authors:  Sofiya Milman; Gil Atzmon; Jill Crandall; Nir Barzilai
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

Review 6.  Cholesterol and prostate cancer.

Authors:  Kristine Pelton; Michael R Freeman; Keith R Solomon
Journal:  Curr Opin Pharmacol       Date:  2012-07-21       Impact factor: 5.547

Review 7.  The link between benign prostatic hyperplasia and prostate cancer.

Authors:  David D Ørsted; Stig E Bojesen
Journal:  Nat Rev Urol       Date:  2012-11-20       Impact factor: 14.432

Review 8.  [Metabolic syndrome and prostate cancer].

Authors:  B J Schmitz-Dräger; G Lümmen; E Bismarck; C Fischer
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

Review 9.  Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.

Authors:  K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano
Journal:  J Endocrinol Invest       Date:  2013-02       Impact factor: 4.256

10.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.